Research programme: oxazolidinones - AstraZeneca

Drug Profile

Research programme: oxazolidinones - AstraZeneca

Alternative Names: Compound 26 (prodrug) - AstraZeneca; Isoxazolino-oxazolidinones - AstraZeneca; Oxazolidinone prodrugs - AstraZeneca

Latest Information Update: 28 Sep 2007

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 28 Sep 2007 Preclinical development is ongoing
  • 09 Feb 2006 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 09 Feb 2006 Preclinical trials in Bacterial infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top